433 related articles for article (PubMed ID: 17900269)
1. Meta analysis: Cancer risk in Barrett's oesophagus.
Thomas T; Abrams KR; De Caestecker JS; Robinson RJ
Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1465-77. PubMed ID: 17900269
[TBL] [Abstract][Full Text] [Related]
2. Barrett's oesophagus: results from a 13-year surveillance programme.
Bani-Hani K; Sue-Ling H; Johnston D; Axon AT; Martin IG
Eur J Gastroenterol Hepatol; 2000 Jun; 12(6):649-54. PubMed ID: 10912484
[TBL] [Abstract][Full Text] [Related]
3. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
4. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
6. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results.
Zaninotto G; Minnei F; Guirroli E; Ceolin M; Battaglia G; Bellumat A; Betetto G; Bozzola L; Cassaro M; Cataudella G; Dal Bò N; Farinati F; Florea G; Furlanetto A; Galliani E; Germanà B; Guerini A; Macrì E; Marcon V; Mastropaolo G; Meggio A; Miori G; Morelli L; Murer B; Norberto L; Togni R; Valiante F; Rugge M
Dig Liver Dis; 2007 Jan; 39(1):18-25. PubMed ID: 17141593
[TBL] [Abstract][Full Text] [Related]
7. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
8. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
9. Review article: Barrett's oesophagus and carcinoma in Japan.
Hongo M
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():50-4. PubMed ID: 15575874
[TBL] [Abstract][Full Text] [Related]
10. Incidence of colorectal cancer in a population-based cohort of patients with Barrett's oesophagus.
Murphy SJ; Anderson LA; Mainie I; Fitzpatrick DA; Johnston BT; Watson RG; Gavin AT; Murray LJ
Scand J Gastroenterol; 2005 Dec; 40(12):1449-53. PubMed ID: 16316894
[TBL] [Abstract][Full Text] [Related]
11. Adenocarcinoma and Barrett's esophagus. An overrated risk?
Spechler SJ; Robbins AH; Rubins HB; Vincent ME; Heeren T; Doos WG; Colton T; Schimmel EM
Gastroenterology; 1984 Oct; 87(4):927-33. PubMed ID: 6468881
[TBL] [Abstract][Full Text] [Related]
12. [Revision needed of follow-up policy for Barrett's esophagus].
Giard RW; Coebergh JW; Ouwendijk RJ
Ned Tijdschr Geneeskd; 2002 Jan; 146(4):150-4. PubMed ID: 11845562
[TBL] [Abstract][Full Text] [Related]
13. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
14. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
15. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
Armstrong D
Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
[TBL] [Abstract][Full Text] [Related]
16. Comparison of methylene blue-directed biopsies and four-quadrant biopsies in the detection of high-grade intraepithelial neoplasia and early cancer in Barrett's oesophagus.
Gossner L; Pech O; May A; Vieth M; Stolte M; Ell C
Dig Liver Dis; 2006 Oct; 38(10):724-9. PubMed ID: 16911879
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of p53 in Barrett's oesophagus.
Krishnadath KK; van Blankenstein M; Tilanus HW
Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
[TBL] [Abstract][Full Text] [Related]
18. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk.
Kelty CJ; Gough MD; Van Wyk Q; Stephenson TJ; Ackroyd R
Scand J Gastroenterol; 2007 Nov; 42(11):1271-4. PubMed ID: 17852872
[TBL] [Abstract][Full Text] [Related]
19. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis.
Corey KE; Schmitz SM; Shaheen NJ
Am J Gastroenterol; 2003 Nov; 98(11):2390-4. PubMed ID: 14638338
[TBL] [Abstract][Full Text] [Related]
20. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
Solaymani-Dodaran M; Logan RF; West J; Card T; Coupland C
Gut; 2004 Aug; 53(8):1070-4. PubMed ID: 15247170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
